Arzerra ofatumumab: Interim Phase III data

Interim data from the open-label, international Phase III HOMER trial in 409 patients with Rituxan rituximab-sensitive indolent B cell NHL who relapsed >=6 months after

Read the full 257 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE